|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 5 (March 1), 1999:
pp. 1778-1779
CORRESPONDENCE
Hepatitis C Virus Infection in Patients With Overt B-Cell
Non-Hodgkin's Lymphoma in a French Center
 |
LETTER |
To the Editor:
Hepatitis C virus (HCV) has been shown to be the main etiologic agent
of type II mixed cryoglobulinemia (MC),1,2 a disease associated with an underlying B-cell clonal proliferation, predisposing to B-cell malignancy, in 2% to 11% of the cases.3 Italian
studies have recently reported a 9% to 35% prevalence of chronic HCV
infection in patients with B-cell non-Hodgkin's lymphomas (B-NHL),
compared with a 2% to 13% prevalence in patients with other blood
malignancies, and a 1% to 5.4% prevalence in healthy
controls.4-9 In addition, a recent American controlled
study10 showed a 22% prevalence of HCV infection markers
in patients with B-NHL versus 5% in age-matched controls. However,
studies from other countries, including the United Kingdom and
Germany,11-14 did not confirm such an association. The aim
of the present study was to determine the prevalence of chronic HCV
infection in a large cohort of unselected patients with B-NHL in a
French center.
Between January 1994 and July 1997, 201 patients with B-NHL (109 men,
92 women; mean age, 56.0 years; range, 18 to 90) were seen at the
hematology clinic of our hospital. During the same period, 94 patients
with Hodgkin's disease were seen (54 men, 40 women; mean age, 37.5 years; range, 18 to 75) and served as a control group for this study.
Lymphoma was diagnosed on the basis of morphologic evaluation of lymph
node tissue or extranodal tissues, including bone marrow specimens.
Immunophenotypic analysis of B- and T-lymphocytic markers was performed
and B-NHL was histologically classified using the Revised European
American Lymphoma (R.E.A.L.) classification.15
Anti-HCV antibodies were prospectively sought in all patients using
second-generation enzyme-linked immunosorbent assay (ELISA), confirmed
by second-generation recombinant immunoblot assay (RIBA)
(Ortho Clinical Diagnostics, Raritan, NJ).
The overall prevalence of HCV markers in the B-NHL patients was 4/201
(2.0%; 95% confidence interval: 0.1% to 3.9%). Table 1 shows the prevalence of HCV markers
according to B-NHL histotypes. The 4 HCV+ patients were
HCV-RNA+ by polymerase chain reaction (PCR).
HCV+ patients had a lymphoplasmatocytoid lymphoma in 1 case, a mucosa-associated lymphoid tissue (MALT) lymphoma
in 1 case, and a diffuse large B-cell lymphoma in 2 cases. The
prevalence of HCV infection in the patients with Hodgkin's disease
(control group) was 1/94 (1.1%; 95% confidence interval: 0.0% to
3.2%). It was not significantly different from the prevalence in
patients with B-NHL.
Overall, the present results do not support the existence of a
significant relationship between HCV infection and B-NHL in France. The
marked discrepancies among studies from different geographic areas
might be explained by the following: (1) the studies4-10 in
favor of a relationship between HCV infection and B-NHL originated from
areas with high endemicity for HCV. However, because of the higher HCV
prevalence in older subjects in these areas, age-matched control groups
should have been used systematically for comparison.5,8 (2)
in contrast, the studies suggesting a lack of
association11-14 originated from countries with a lower prevalence of HCV infection. Thus, HCV appears to be associated with
B-NHL only in areas where HCV is highly prevalent, suggesting that HCV
is not essentially involved in the pathogenesis of B-NHL. However, some
specific B-NHL histotypes could be preferentially associated with HCV
infection. It is noteworthy that, in three studies,6-8 HCV
was principally found in patients with lymphoplasmacytoid lymphoma/immunocytoma associated with type II MC, with 30% to 45% of
these patients being HCV-RNA+.6-8 The
lymphoplasmatocytoid lymphoma/immunocytoma originates from a
CD5-peripheral B lymphocyte able to differentiate into a plasma cell.
Sites involved include bone marrow, lymph nodes, spleen and, less
frequently, peripheral blood or extranodal sites. This condition is
commonly associated with type II MC.16 In the United States
study,10 monocytoid nodal B-cell lymphoma accounted for
23% of all lymphomas and 67% of all low-grade lymphomas among the
HCV+ patients. Furthermore, another Italian
report17 pointed out an additional subset of overt B-NHL in
HCV-infected individuals, diffuse large B-cell lymphoma (23 of 83, 27.7% of cases were HCV+).
The overrepresentation of lymphoplasmatocytoid lymphoma in several
Italian studies (14% to 33%)6,7 might result from a
selection bias of the patients, due to the follow-up of a significant number of patients with MC in these centers. This could account for the
high prevalence of HCV infection in B-NHL patients in these series. The
lower prevalence of lymphoplasmatocytoid lymphoma in our series of
unselected patients with B-NHL (4.5%) is in agreement with the 1.2%
prevalence, as estimated by R.E.A.L.,15 and could explain
the low prevalence of HCV markers observed. Furthermore, the low
prevalence of HCV infection (2 of 118, 1.7%) in the large cohort of
our patients with diffuse large B-cell lymphoma does not confirm the
recently suggested association between HCV and diffuse large B-cell
lymphoma.17 Prospective case-control studies of the
prevalence of HCV in B-NHL patients from different countries, including
all R.E.A.L. histological subtypes in sufficient numbers, are now
mandated to confirm such an association.
Georgios Germanidis
Corinne Haioun
Jérôme Pourquier
Philippe Gaulard
Jean-Michel Pawlotsky
Daniel Dhumeaux
Félix Reyes
Hôpital
Henri Mondor
Université Paris XII
Créteil,
France
| |
REFERENCES |
1.
Agnello V:
Hepatitis C virus infection and type II cryoglobulinemia: An immunological perspective.
Hepatology
26:375, 1997
2.
Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia M, André C, Voisin M-C, Intrator L, Zafrani E-S, Duval J, Dhumeaux D:
Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.
Ann Intern Med
122:169, 1995[Abstract/Free Full Text]
3.
Gorevic PD, Frangione B:
Mixed cryoglobulinemia cross-reactive idiotypes: Implications for the relationship of MC to rheumatic and lymphoproliferative diseases.
Semin Hematol
28:79, 1991[Medline]
[Order article via Infotrieve]
4.
Zignego AL, Ferri C, Giannini C, Caracciolo F, Monti M, La Civita L, Careccia G, Longombardo G, Bellesi G, Innocenti F, Thiers V, Gentilini P:
HCV infection in B-cell non-Hodgkin's lymphoma.
J Hepatol
23:77, 1995 (abstr, suppl 1)
5.
Pioltelli P, Zehender G, Monti G, Monteverde A, Galli M:
HCV and non-Hodgkin lymphoma.
Lancet
347:624, 1996[Medline]
[Order article via Infotrieve] (letter)
6.
Mazzaro C, Zagonel V, Monfardini S, Tulissi P, Pussini E, Fanni M, Sorio R, Bortolus R, Crovatto M, Santini G, Tiribelli C, Sasso F, Masutti R, Pozzato G:
Hepatitis C virus and non-Hodgkin's lymphomas.
Br J Haematol
94:544, 1996[Medline]
[Order article via Infotrieve]
7.
Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, Russo D, Falasca E, Botta GA, Baccarani M:
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders.
Blood
87:4296, 1996[Abstract/Free Full Text]
8.
Musto P, Dell'Olio M, Carotenuto M, Mangia A, Andriulli A:
Hepatitis C virus infection: A new bridge between hematologists and gastroenterologists?
Blood
88:752, 1996[Free Full Text] (letter)
9.
Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca R, Morselli M, Valenti C, Mascia T, Vandelli L, Vallisa D, Cavanna L, Torelli G:
Clinico-pathological characterization of hepatitis C virus-related B-cell non Hodgkin's lymphomas without symptomatic cryoglobulinemia.
Ann Oncol
9:495, 1998[Abstract/Free Full Text]
10.
Zuckerman E, Zuckerman T, Levine A, Douer D, Gutekunst K, Mizokami M, Qian D, Velankar M, Nathwani BN, Fong TL:
Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.
Ann Intern Med
127:423, 1997[Abstract/Free Full Text]
11.
Hanley J, Jarvis L, Simmonds P, Parker A, Ludlam C:
HCV and non-Hodgkin lymphoma.
Lancet
347:1339, 1996[Medline]
[Order article via Infotrieve] (letter)
12.
Brind AM, Watson JP, Burt A, Kestevan P, Wallis J, Proctor SJ, Bassendine MF:
Non-Hodgkin's lymphoma and hepatitis C virus infection.
Leuk Lymphoma
21:127, 1996[Medline]
[Order article via Infotrieve]
13.
Thalen DJ, Raemaekers J, Galama J, Cooreman MP:
Absence of hepatitis C virus infection in non-Hodgkin's lymphoma.
Br J Haematol
96:880, 1997[Medline]
[Order article via Infotrieve] (letter)
14.
Ellenrieder V, Weidenbach H, Frickhofen N, Michel D, Prummer O, Klatt S, Bernas O, Mertens T, Adler G, Beckh K:
HCV and HGV in B-cell non-Hodgkin's lymphoma.
J Hepatol
28:34, 1998[Medline]
[Order article via Infotrieve]
15.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA:
A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group.
Blood
84:1361, 1994[Free Full Text]
16.
Silvestri F, Barillari G, Fanin R, Salmaso F, Pipan C, Falasca E, Puglisi F, Mariuzzi L, Zaja F, Infanti L, Patriarca F, Candoni A, Rogato A, Di Loreto C, Botta GA, Baccarani M:
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma.
Ann Oncol
9:499, 1998[Abstract/Free Full Text]
17.
De Vita S, Sacco C, Sansonno D, Gloghini A, Dammacco F, Crovatto M, Santini G, Dolcetti R, Boiocchi M, Carbone A, Zagonel V:
Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection.
Blood
90:776, 1997[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub
Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation
Rheumatology,
August 1, 2007;
46(8):
1234 - 1242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Besson, D. Canioni, E. Lepage, S. Pol, P. Morel, P. Lederlin, A. Van Hoof, H. Tilly, P. Gaulard, B. Coiffier, et al.
Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Positive Patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs
J. Clin. Oncol.,
February 20, 2006;
24(6):
953 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D Cowgill, C. A Loffredo, S. A.-L. Eissa, N. Mokhtar, M. Abdel-Hamid, A. Fahmy, and G T. Strickland
Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt
Int. J. Epidemiol.,
October 1, 2004;
33(5):
1034 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Morton, E. A. Engels, T. R. Holford, B. Leaderer, Y. Zhang, S. H. Zahm, P. Boyle, B. Zhang, S. Flynn, G. Tallini, et al.
Hepatitis C Virus and Risk of Non-Hodgkin Lymphoma: A Population-Based Case-Control Study among Connecticut Women
Cancer Epidemiol. Biomarkers Prev.,
March 1, 2004;
13(3):
425 - 430.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
O. Hermine, F. Lefrere, J.-P. Bronowicki, X. Mariette, K. Jondeau, V. Eclache-Saudreau, B. Delmas, F. Valensi, P. Cacoub, C. Brechot, et al.
Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection
N. Engl. J. Med.,
July 11, 2002;
347(2):
89 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Rabkin, B. H. Tess, R. E. Christianson, W. E. Wright, D. J. Waters, H. J. Alter, and B. J. van den Berg
Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia
Blood,
May 13, 2002;
99(11):
4240 - 4242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Udomsakdi-Auewarakul, P. Auewarakul, S. Sukpanichnant, and W. Muangsup
Hepatitis C virus infection in patients with non-Hodgkin lymphoma in Thailand
Blood,
June 1, 2000;
95(11):
3640 - 3641.
[Full Text]
[PDF]
|
|
|
|
|
